MARKET

ORIC

ORIC

ORIC PHARMACEUTICALS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.16
-0.10
-0.32%
Opening 11:12 07/02 EDT
OPEN
31.60
PREV CLOSE
31.26
HIGH
33.46
LOW
30.15
VOLUME
34.33K
TURNOVER
--
52 WEEK HIGH
40.67
52 WEEK LOW
24.26
MARKET CAP
931.78M
P/E (TTM)
-31.9230
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ORIC stock price target is 42.75 with a high estimate of 48.00 and a low estimate of 35.00.

EPS

ORIC News

More
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 6d ago
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II
GlobeNewswire · 06/22 14:00
ORIC Pharmaceuticals Presents Preclinical Data On Glucocorticoid Receptor Antagonist And CD73 Inhibitor Programs At The 2020 American Association For Cancer Research Virtual Annual Meeting II
SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic
Benzinga · 06/22 13:06
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
GlobeNewswire · 06/09 21:15
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 12:13
ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
GlobeNewswire · 05/27 11:30
ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address.
GlobeNewswire · 05/26 10:30
ORIC Pharmaceuticals EPS misses by $3.96
ORIC Pharmaceuticals (NASDAQ:ORIC): Q1 GAAP EPS of -$4.46 misses by $3.96. Cash and equivalents of $79.44M (-10.9% Q/Q) Press Release
seekingalpha · 05/21 01:20

Industry

Biotechnology & Medical Research
+0.41%
Pharmaceuticals & Medical Research
+0.37%

Hot Stocks

Symbol
Price
%Change

About ORIC

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, potent and selective, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens.
More

Webull offers kinds of ORIC Pharmaceuticals Inc stock information, including NASDAQ:ORIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORIC stock methods without spending real money on the virtual paper trading platform.